Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.59 |
| ▸ | KDR | P35968 | 5/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601714 | 0.89 | LTA4H (0.53) | LTA4HHRH3BACE1SRC | |
| SCHEMBL3601677 | 0.89 | ESR1 (0.55) | KDRJAK2JAK3PTK2 | |
| SCHEMBL13165639 | 0.89 | LTA4H (0.53) | LTA4HKDRJAK2JAK3PTK2 | |
| SCHEMBL3602236 | 0.86 | LTA4H (0.51) | LTA4HKDRJAK2JAK3HRH3 | |
| SCHEMBL3605900 | 0.85 | FLT1 (0.52) | LTA4HKDRHRH3HRH2PSMB1 | |
| SCHEMBL11877770 | 0.80 | HRH3 (0.83) | LTA4HHRH3HRH2PSMB1PSMB5 | |
| SCHEMBL11877113 | 0.79 | HRH3 (0.86) | LTA4HHRH3HRH2PSMB1PSMB5 | |
| SCHEMBL11882995 | 0.79 | HRH3 (0.86) | LTA4HHRH3HRH2PSMB1PSMB5 | |
| SCHEMBL6331969 | 0.78 | KDR (0.67) | KDR | |
| SCHEMBL6336620 | 0.78 | KDR (0.74) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | claimed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | claimed |
| JP-2007511484-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-9655882-B2 | Compositions and methods for treatment of neurodegenerative disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-9162981-B2 | Compositions and methods for treatment of neurodegenerative disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150258061-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-09-17 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | LTA4H 4512/4885KDR 8/4885JAK2 6/4885 |
| US-20150258061-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | LTA4H 1259/4885KDR 4527/4885JAK2 4588/4885 |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | LTA4H 1259/4885KDR 4527/4885JAK2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.